FDA delays mifepristone safety report until March, court filing says
The FDA told a federal court it will not finalize its safety review of mifepristone until March and will not add new restrictions before then. The agency is also examining the risk program that governs how the abortion pill is distributed and prescribed, a process that could take longer. Abortion rights advocates called the review a political delay, while anti-abortion groups have criticized the administration's pace.
Expanded Detail
EXPANDED:
The FDA told a Louisiana federal court it will not complete its mifepristone safety report until March and will hold off on new restrictions
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “FDA: Mifepristone review won’t be done until March.” Browse more stories.